Search
Bioatla Inc
BCABAdd to Watchlist
4.190USD
+0.105+2.57%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.32MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.57%
5 Days
+13.86%
1 Month
+20.06%
6 Months
+684.35%
Year to Date
+638.07%
1 Year
+1014.07%
Key Figures
4.010Open
4.300High
38.17KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
3.01%Turnover Ratio
4.085Prev. Close
4.000Low
124.74KTurnover
LossP/E Static
-0.15P/B
0.00%Div Yield TTM
-216.05%ROA
71.50052wk High
1.26Volume Ratio
-69.78MNet Profit
1.27MShares
-248.7340EPS TTM
0.79Beta
-813.88%ROE
3.26052wk Low
7.34%Amplitude
100.00%Gross Margin
5.32MMarket Cap
2.10Reward/Risk
8.11%Risk Rate
TradingKey Stock Score of Bioatla Inc
Currency: USD Updated: 2026-07-02Key Insights
Bioatla Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bioatla Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Bioatla Inc Highlights
StrengthsRisks
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.00M.
Overvalued
The company’s latest PE is -0.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 326.93K shares, decreasing 54.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
10.000
Target Price
+6427.42%
Upside Space
Bioatla Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bioatla Inc Info
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Ticker SymbolBCAB
CompanyBioatla Inc
CEOShort (Jay M)
Websitehttps://www.bioatla.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Bioatla Inc (BCAB)?
The current price of Bioatla Inc (BCAB) is 4.19.
What is the symbol of Bioatla Inc?
The ticker symbol of Bioatla Inc is BCAB.
What is the 52-week high of Bioatla Inc?
The 52-week high of Bioatla Inc is 71.50.
What is the 52-week low of Bioatla Inc?
The 52-week low of Bioatla Inc is 3.26.
What is the market capitalization of Bioatla Inc?
The market capitalization of Bioatla Inc is 5.32M.
Is Bioatla Inc (BCAB) currently rated as Buy, Hold, or Sell?
According to analysts, Bioatla Inc (BCAB) has an overall rating of STRONG BUY, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of Bioatla Inc (BCAB)?
The Earnings Per Share (EPS TTM) of Bioatla Inc (BCAB) is -50.66.